USE OF TRIPHASIC CT LI-RADS V 2018 IN PATIENTS UNDERGOING DYNAMIC CONTRAST-ENHANCED CT LIVER FOR HEPATIC LESION CHARACTERIZATION

Humaira Anjum; Samia Iftikhar

doi:10.37762/jgmds.13-1.767

Authors

Humaira Anjum Khyber Teaching Hospital, Peshawar
Samia Iftikhar Khyber Teaching Hospital, Peshawar

DOI:

https://doi.org/10.37762/jgmds.13-1.767

Keywords:

Hepatocellular Carcinoma, Liver Imaging Reporting and Data System (LI-RADS), Dynamic Contrast-Enhanced CT, Triphasic CT, Pakistan

Abstract

ABSTRACT

OBJECTIVES

This study aimed to characterize hepatic observations and evaluate the frequency of LI-RADS v2018 categories in a high-risk Pakistani population using triphasic CT.

METHODOLOGY

A retrospective cross-sectional observational study was conducted at the Radiology Department of Khyber Teaching Hospital in Peshawar from March 2021 to September 2022. Fifty-five high-risk patients (cirrhosis/chronic hepatitis B) underwent triphasic CT, and 80 Observations were independently categorized by two radiologists using LI-RADS v2018 major features. Histopathological correlation was assessed where available.

RESULTS
Out of 55 patients (80 observations) in our study, the LI-RADS distribution was: LR-5 in 61 (76.25%), LR-4 in 4 (5%), LR-M in 3 (3.75%), LR-TIV in 7 (8.75%), LR-1/2/3 in 5 (6.25%). Non-rem arterial phase hyperenhancement was the most frequent feature (81.3%). All LR-5 lesions showed non-rim APHE and washout. In the subset with histopathology (n=12), LR-5 showed 100% concordance with HCC (7/7), and LR-M showed 100% concordance with cholangiocarcinoma (3/3).

CONCLUSION

Triphasic CT LI-RADS v2018 effectively categorized hepatic findings in high-risk Pakistani patients, with LR-5 being the most frequent category and demonstrating strong histopathological correlation; however, the high LR-5 prevalence suggests potential selection bias inherent to the referral-based setting. The system provides a standardized reporting framework suitable for local clinical practice.

KEYWORDS: Hepatocellular Carcinoma, Liver Imaging Reporting and Data System (LI-RADS), Dynamic Contrast-Enhanced CT, Triphasic CT, Pakistan

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biographies

Humaira Anjum, Khyber Teaching Hospital, Peshawar

Associate Professor,
Department of Radiology,
Khyber Teaching Hospital, Peshawar

Samia Iftikhar, Khyber Teaching Hospital, Peshawar

Medical Officer,
Department of Radiology,
Khyber Teaching Hospital, Peshawar

References

Cunha GM, Fowler KJ, Roudenko A, Taouli B, Fung AW, Elsayes KM, et al. How to use LI-RADS to report liver CT and MRI observations. Radiographics. 2021 Sep- Oct;41(5):1352-67. https://doi.org/10.1148/rg.2021210003. PMID: 34432443 DOI: https://doi.org/10.1148/rg.2021200205

Cerny M, Bergeron C, Billiard JS, Murphy-Lavallée J, Olivié D, Bérubé J, et al. LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology. 2018 Jul;288(1):118-28. https://doi.org/10.1148/radiol.2018171920. PMID: 29624486 DOI: https://doi.org/10.1148/radiol.2018171678

De Santis A, Gallusi G. Diagnostic imaging for hepatocellular carcinoma. Hepatoma Res. 2019;5:1. https://doi.org/10.20517/2394-5079.2018.97 DOI: https://doi.org/10.20517/2394-5079.2018.65

Jha RC, Mitchell DG, Weinreb JC, Santillan CS, Yeh BM, Francois R, et al. LI-RADS categorization of benign and likely benign findings in patients at risk of hepatocellular carcinoma: a pictorial atlas. AJR Am J Roentgenol. 2014;203(1):W48–69. https://doi.org/10.2214/AJR.13.11530. PMID: 24951233 DOI: https://doi.org/10.2214/AJR.13.12169

Elsayes KM, Hooker JC, Agrons MM, Kielar AZ, Tang A, Fowler KJ, et al. 2017 version of LI-RADS for CT and MR imaging: an update. Radiographics. 2017 Nov–Dec;37(7):1994–2017. https://doi.org/10.1148/rg.2017170099. PMID: 29131712 DOI: https://doi.org/10.1148/rg.2017170098

Santillan C. CT and MRI of the liver for hepatocellular carcinoma. Hepatoma Res. 2020;6:63. https://doi.org/10.20517/2394-5079.2020.60 DOI: https://doi.org/10.20517/2394-5079.2020.60

American College of Radiology Committee on LI-RADS® (Liver). CT/MRI LI-RADS® PowerPoint Presentation. Reston, VA: American College of Radiology; 2022. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/Presentations

Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018 Dec;289(3):816–30. https://doi.org/10.1148/radiol.2018181494. PMID: 30403565 DOI: https://doi.org/10.1148/radiol.2018181494

Bhatti ABH, Sheikh AAE, Mahmud US, Zeeshan S, Khan NY, Zia HH, et al. Clinical profile and treatment of hepatocellular carcinoma: a single-center experience. South Asian J Cancer. 2021 Apr;10(2):76-80. https://doi.org/10.1055/s-0041-1731101. PMID: 34230706 DOI: https://doi.org/10.1055/s-0041-1729451

Parkash O, Hamid S. Next big threat for Pakistan: hepatocellular carcinoma (HCC). J Pak Med Assoc. 2016 Jun;66(6):735–9. PMID: 27339578

Tang ES, Hall G, Yu D, Menard A, Hopman W, Nanji S. Predictors and cumulative frequency of hepatocellular carcinoma in high and intermediate LI-RADS lesions: a cohort study from a Canadian academic institution. Ann Surg Oncol. 2019 Aug;26(8):2560–7. https://doi.org/10.1245/s10434-019-07386-9. PMID: 31025229 DOI: https://doi.org/10.1245/s10434-019-07386-9

Granata V, Fusco R, Setola SV, Sandomenico F, Barretta ML, Belli A, et al. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular–cholangiocarcinoma. Radiol Oncol. 2020 May 28;54(2):149–58. https://doi.org/10.2478/raon-2020-0029. PMID: 32463393 DOI: https://doi.org/10.2478/raon-2020-0029

van der Pol CB, McInnes MDF, Salameh JP, Levis B, Chernyak V, Sirlin C, et al. CT/MRI and CEUS LI-RADS major features association with hepatocellular carcinoma: individual patient data meta-analysis. Radiology. 2022 Feb;302(2):326-35. https://doi.org/10.1148/radiol.2021212493. PMID: 34734976 DOI: https://doi.org/10.1148/radiol.2021211244

Cho MJ, An C, Aljoqiman KS, et al. Diagnostic performance of Liver Imaging Reporting and Data System in patients at risk of both hepatocellular carcinoma and metastasis. Abdom Radiol (NY). 2020;45(12):3789–99. https://doi.org/10.1007/s00261-020-02684-z. PMID: 32556789 DOI: https://doi.org/10.1007/s00261-020-02581-9

Khanna G, Chavhan GB, Schooler GR, Fraum TJ, Alazraki AL, Squires JH, et al. Diagnostic performance of LI-RADS version 2018 for evaluation of pediatric hepatocellular carcinoma. Radiology. 2021 Apr;299(1):190–9. https://doi.org/10.1148/radiol.2021203138. PMID: 33382160 DOI: https://doi.org/10.1148/radiol.2021203559

Kim H, Choi JI, Kim BH, Youn SY, Kim H, Kim DH, Rha SE. LI-RADS version 2018 in patients with prior history of hepatocellular carcinoma: are LR-4 observations enough for the diagnosis of recurrent HCC? Investig Magn Reson Imaging. 2021 Sep;25(3):172–82. https://doi.org/10.13104/imri.2021.25.3.172 DOI: https://doi.org/10.13104/imri.2021.25.3.172

Dunn C, Lin B, Rich NE, Patel MS, Gopal P, Singal AG. Correlation of LI-RADS 3 or 4 observations with histopathologic diagnosis in patients with cirrhosis. Clin Gastroenterol Hepatol. 2023 May;21(5):1351-3.e2. https://doi.org/10.1016/j.cgh.2022.03.009. PMID: 35307596 DOI: https://doi.org/10.1016/j.cgh.2022.03.009

Cannella R, Matteini F, Dioguardi Burgio M, Sartoris R, Beaufrere A, Calderaro J, Mule S, Reizine E, Luciani A, Laurent A, Seror O. Association of LI-RADS and histopathologic features with survival in patients with solitary resected hepatocellular carcinoma. Radiology. 2024 Feb;310(2):e231160. https://doi.org/10.1148/radiol.231160. PMID: 38398656 DOI: https://doi.org/10.1148/radiol.231160